CCND1 and renal carcinoma: We evaluated vorinostat as a therapeutic candidate against cyclin D1 in lung cancer cells because vorinostat is known to suppress cyclin D1 expression in mantle cell lymphoma cells [14], colon cancer cells [15], renal cancer cells [16], and JB6 mouse epidermal Cl 41 cells [17] and because cyclin D1 overexpression was significantly associated with poor RFS in stage II-IIIA lung adenocarcinoma (Fig. 2).